Improving CKD-MBD management in haemodialysis patients: Barrier analysis for implementing better practice

Nephrology Dialysis Transplantation

Volumn 26, Issue 4, 2011, Pages 1319-1326

  Toussaint, Nigel D ^a,b   Pedagogos, Eugenie ^b   Beavis, Jennifer ^b   Becker, Gavin J ^b   Polkinghorne, Kevan R ^a   Kerr, Peter G ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

chronic kidney disease; CKD MBD; evidencepractice gap; haemodialysis; mineral metabolism

Indexed keywords

25 HYDROXYVITAMIN D; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM CARBONATE; LANTHANUM CARBONATE; MAGNESIUM; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ADULT; ARTICLE; BONE DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL AND BONE DISORDER; NEPHROLOGIST; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; BONE DISEASES, METABOLIC; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RENAL DIALYSIS; YOUNG ADULT;

EID: 79953902518     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq602     Document Type: Article

References (33)

1. Foley R, Parfrey P, Samak M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119 (Pubitemid 28527268)
2. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056 (Pubitemid 40862092)
3. Block G, Hulbert-Shearon T, Levin N et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
4. London G, Guerin A, Marchais S et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740 (Pubitemid 37098542)
5. Moe SM, Drueke T, Lameire N et al. Chronic kidney disease - mineral and bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14: 3-12 (Pubitemid 46014534)
6. Al Aly Z, Gonzalez EA, Martin KJ et al. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004; 24: 422-426 (Pubitemid 39279384)
7. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187 (Pubitemid 41623345)
8. Wazny LD, Raymond CB, Lesperance EM et al. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program. CANNT J 2008; 18: 36-41
9. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997; 157: 408-416 (Pubitemid 27384745)
10. Elder G, Faull R, Branley P et al. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 2006; 11: S230-S261
11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42: S1-S201
12. European Best Practice Guidelines. http://www.era-edta.org/ebpg. htm (12 July 2010, date last accessed)
13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S1-S130
14. McDonald S, Excell L, Livingston B. ANZDATA Registry Report 2008. Adelaide, South Australia: Australian and New Zealand Dialysis and Transplant Registry, 2009
15. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138 (Pubitemid 32880350)
16. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218 (Pubitemid 39031360)
17. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779 (Pubitemid 38294808)
18. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: S34-S38 (Pubitemid 39369939)
19. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932 (Pubitemid 41505468)
20. Block GA, Port F. Re-evaluation of risks associated with hyperpho-sphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237 (Pubitemid 30354431)
21. Hulscher MEJL, Wensing M, Grol RPTM et al. Interventions to improve the delivery of preventive services in primary care. Am J Public Health 1999; 89: 737-746 (Pubitemid 29282739)
22. Grol R, Wensing M, Eccles M. Improving Patient Care. Toronto: Elsevier Limited, 2005
23. Kuhlmann MK, Hoechst S, Landthaler I. Patient empowerment in the management of hyperphosphatemia. Int J Artif Organs 2007; 30: 1008-1013
24. Shaw-Stuart NJ, Stuart A. The effect of an educational patient compliance program on serum phosphate levels in patients receiving hemodialysis. J Ren Nutr 2000; 10: 80-84
25. Ashurst Ide B, Dobbie H. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. J Ren Nutr 2003; 13: 267-274 (Pubitemid 38367740)
26. Ford JC, Pope JF, Hunt AE et al. The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia. J Ren Nutr 2004; 14: 36-44 (Pubitemid 38121616)
27. Yokum D, Glass G, Cheung CF et al. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr 2008; 18: 521-529
28. Reddy V, Symes F, Sethi N et al. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population. J Ren Nutr 2009; 19: 314-320
29. Ahlenstiel T, Pape L, Ehrich JH et al. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3241-3249
30. Arenas MD, Alvarez-Ude F, Gil MT et al. Application of NKF-K/ DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006; 21: 1663-1668 (Pubitemid 43834646)
31. Wald R, Tentori F, Tighiouart H et al. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis 2007; 49: 257-266 (Pubitemid 46178400)
32. Meetoo D. Clinical skills: empowering people with diabetes to minimize complications. Br J Nurs 2004; 13: 644-651
33. Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract 2005; 55: 875-882 (Pubitemid 41684003)